Outcome after failure of second generation tyrosine Kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 4, 2013, Pages 477-484

  Eghtedar, Alireza ^a   Kantarjian, Hagop ^a   Jabbour, Elias ^a   O'Brien, Susan ^a   Burton, Elizabeth ^a   Garcia Manero, Guillermo ^a   Verstovsek, Srdan ^a   Ravandi, Farhad ^a   Borthakur, Gautam ^a   Konopleva, Marina ^a   Quintas Cardama, Alfonso ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

CML; Dasatinib; Discontinuation; Nilotinib; TKIs

Indexed keywords

BAFETINIB; CYCLOPHOSPHAMIDE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ASTHMA; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERBILIRUBINEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATITIS; PATIENT COMPLIANCE; PATIENT PREFERENCE; PERICARDIAL EFFUSION; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

CML; DASATINIB; DISCONTINUATION; NILOTINIB; TKIS;

ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880762649     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.02.025     Document Type: Article

References (26)

1. S.G. O'Brien, F. Guilhot, and R.A. Larson Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004 (Pubitemid 36302244)
2. H. de Lavallade, J.F. Apperley, and J.S. Khorashad Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis J Clin Oncol 26 2008 3358 3363
3. B.J. Druker, F. Guilhot, and S.G. O'Brien Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417 (Pubitemid 44903745)
4. A. Hochhaus, S.G. O'Brien, and F. Guilhot Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 23 2009 1054 1061
5. T.P. Hughes, J. Kaeda, and S. Branford Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 2003 1423 1432 (Pubitemid 37211057)
6. H.M. Kantarjian, M. Talpaz, and S. O'Brien Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia Blood 108 2006 1835 1840 (Pubitemid 44394991)
7. O'Brien SG, Guilhot F, Goldman JM, et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). ASH Annual Meeting Abstracts 2008; 112 (abstract 186).
8. A. Hochhaus, M. Baccarani, and M. Deininger Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib Leukemia 22 2008 1200 1206 (Pubitemid 351833788)
9. H.M. Kantarjian, F.J. Giles, and K.N. Bhalla Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results Blood 117 2010 1141 1145
10. N.P. Shah, D.W. Kim, and H. Kantarjian Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib Haematologica 95 2011 232 240
11. J.E. Cortes, H.M. Kantarjian, and T.H. Brummendorf Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib Blood 118 2011 4567 4576
12. J.E. Cortes, D. Jones, and S. O'Brien Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase J Clin Oncol 28 2010 392 397
13. J.E. Cortes, D. Jones, and S. O'Brien Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia J Clin Oncol 28 2010 398 404
14. G. Rosti, F. Palandri, and F. Castagnetti Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia Blood 114 2009 4933 4938
15. G. Saglio, D.W. Kim, and S. Issaragrisil Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 2010 2251 2259
16. J.E. Cortes, D.W. Kim, and H.M. Kantarjian Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial J Clin Oncol 30 2012 3486 3492
17. H. Kantarjian, N.P. Shah, and A. Hochhaus Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 2010 2260 2270
18. M. Talpaz, R.T. Silver, and B.J. Druker Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 99 2002 1928 1937 (Pubitemid 34525471)
19. M. Baccarani, G. Saglio, and J. Goldman Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 2006 1809 1820 (Pubitemid 44394987)
20. H.M. Kantarjian, N.P. Shah, and J.E. Cortes Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeoid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) Blood 119 2012 1123 1129
21. F. Saglio The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: 24-month follow-up J Clin Oncol 29 suppl 2011 (abstract 6502)
22. J.E. Cortes, A. Hochhaus, and P.D. le Coutre Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib Blood 117 2011 5600 5606
23. R. Garg, H.M. Kantarjian, and S. O'Brien The use of nilotinib or dasatinib after failure to 2 prior tyrodine kinase inhibitors: long term follow-up Blood 114 2009 4361 4368
24. J.E. Cortes, H.M. Kantarjian, and N.P. Shah Ponatinib in refractory Philadelphia chromosome-positive leukemias N Engl J Med 367 2012 2075 2088
25. J.E. Cortes, J.H. Lipton, and D. Rea Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation Blood 120 2012 2573 2580
26. H.J. Khoury, J.E. Cortes, and H.M. Kantarjian Bosutinib is active in chronic pahse chronic myleoid leukemia after imatinib and dasatinib and/or nilotinib therspy failure Blood 119 2012 3403 3412